DeepMed Research

Tucidinostat

Generic Name: Tucidinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Clinical Trials

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Relapsed/Refractory Non-Hodgkin Lymphoma
Advanced Solid Tumors

Interventions: Drug: Chidamide
Drug: Decitabine
Drug: Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）

First Posted Date: 2022-04-11

Last Posted Date: 2022-04-11

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 100

Registration Number: NCT05320640

Locations: 🇨🇳
Biotherapeutic Department, Chinese PLA General Hospital, Beijing, Beijing, China

Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Phase 1

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: chidamide
Drug: celecoxib

First Posted Date: 2022-03-16

Last Posted Date: 2024-12-20

Lead Sponsor: Taipei Medical University Shuang Ho Hospital

Target Recruit Count: 9

Registration Number: NCT05281276

Locations: 🇨🇳
Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Conditions: Breast Cancer

Interventions: Drug: Tucidinostat

First Posted Date: 2022-03-11

Last Posted Date: 2022-03-11

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 50

Registration Number: NCT05276713

Locations: 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Phase 1

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Azacitidine
Drug: Chidamide

First Posted Date: 2022-03-08

Last Posted Date: 2022-09-14

Lead Sponsor: Zhujiang Hospital

Target Recruit Count: 20

Registration Number: NCT05270200

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guandong, China

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Chidamide combined with exemestane (+/- goserelin)
Drug: Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)

First Posted Date: 2022-02-23

Last Posted Date: 2022-02-23

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 130

Registration Number: NCT05253066

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: NHL, Adult

Interventions: Drug: APG-1252
Drug: Chidamide

First Posted Date: 2022-01-11

Last Posted Date: 2024-01-23

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 51

Registration Number: NCT05186012

Locations: 🇨🇳
Henan Provincial Oncology Hospital, Zhengzhou, Henanan, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Shanghai Jiao Tong University school of medicine Ruijin Hospital, Shanghai, China

and more 1 locations

Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Phase 2

Conditions: Angioimmunoblastic T-cell Lymphoma

Interventions: Drug: Azacitidine
Drug: Chidamide

First Posted Date: 2022-01-05

Last Posted Date: 2022-01-05

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT05179213

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

Interventions: Drug: Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab

First Posted Date: 2021-12-20

Last Posted Date: 2023-03-06

Lead Sponsor: Ruihua Xu

Target Recruit Count: 87

Registration Number: NCT05163483

Locations: 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China

Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD

Phase 1

Conditions: Safety and Efficacy

Interventions: Drug: Chidamide

First Posted Date: 2021-12-01

Last Posted Date: 2021-12-01

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 20

Registration Number: NCT05140616

Locations: 🇨🇳
First Affiliated Hospital,Soochow University, Suzhou, Jiangsu, China

Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH

Not Applicable

Conditions: Chidamide
Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Chidamide combines with VP-16 and methylprednisolone

First Posted Date: 2021-11-30

Last Posted Date: 2021-11-30

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 20

Registration Number: NCT05137522

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy